The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Interventions for valvular disease and heart failure

Transaxillary compared with transcarotid access for TAVR: a propensity-matched comparison from a French multicentre registry

EuroIntervention 2020;16:842-849. DOI: 10.4244/EIJ-D-20-00117

1. Heart Team, Institute Cœur-Poumons, CHU Lille, Lille, France; 2. National Institute of Health and Medical Research U1011, Lille, France; 3. Groupement des Hôpitaux de l’Institut Catholique de Lille (GHICL), Cardiology Department, Lomme, France; 4. Heart Team, Hôpital Marie Lannelongue, Le Plessis Robinson, France; 5. Heart Team, CHU Montpellier, Montpellier, France; 6. Heart Team, CH Lens, Lens, France; 7. Heart Team, CHU Nîmes, Nîmes, France; 8. Department of Biostatics, EA 2694 - Santé publique: épidémiologie et qualité des soins, Univ. Lille, CHU Lille, Lille, France

Aims: No randomised study comparing the outcomes of transcarotid (TC) and transaxillary (TAx) TAVR has been conducted to date. The purpose of this study was to understand which approach should be the preferred alternative by comparing their outcomes using a propensity-matched comparison in a French multicentre registry.

Methods and results: From 2010 to 2018, a French multicentre prospective registry included 502 patients, with 374 undergoing TC-TAVR and 128 TAx-TAVR for symptomatic aortic stenosis. Patients treated through TAx access were matched 1:2 with patients treated through the TC route by using a propensity score (20 clinical, anatomical and procedural variables) and by date of the procedure. The first outcome was mortality at one-month follow-up. The second outcome was one-month stroke/transient ischaemic attack (TIA). In propensity-matched analyses, the incidence of the primary outcome was similar in the TAx and TC groups (TAx 5.5% vs TC 4.5%, OR 1.23, 95% CI: 0.40-3.70). The secondary outcome was similar in TAx (3.2%) and TC (6.8%, OR 0.52, 95% CI: 0.14-1.84). Minor bleeding (2.7% vs 9.3%, OR 0.26, 95% CI: 0.07-0.92) and main access haematoma (3.6% vs 10.3%, OR 0.034, 95% CI: 0.09-0.92) were significantly more frequent with the TC access. One-month clinical efficacy and safety and one-year mortality did not differ according to the different routes.

Conclusions: One-month mortality, one-month stroke/TIA and one-year mortality are similar with TAx-TAVR and TC-TAVR. However, TC-TAVR is accompanied by more minor bleeding and main access haematoma compared with the transaxillary route.

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Thirty-day clinical outcomes of the Evolut PRO self-expanding transcatheter aortic valve: the international FORWARD PRO study